Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | FNTA | P49354 | 6/20 | 0.38 |
| ▸ | FNTB | P49356 | 6/20 | 0.38 |
| ▸ | CTSD | P07339 | 5/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550853 | 0.89 | BACE1 (0.47) | BACE1FNTAFNTBCTSD | |
| SCHEMBL29445230 | 0.88 | FNTA (0.43) | FNTAFNTB | |
| SCHEMBL30051524 | 0.86 | MME (0.46) | FNTAFNTBMMEACECPA1 | |
| SCHEMBL30867027 | 0.85 | BACE1 (0.44) | BACE1FNTAFNTBENPEP | |
| SCHEMBL31013513 | 0.84 | CTSD (0.43) | BACE1CTSD | |
| SCHEMBL29551131 | 0.83 | MME (0.41) | CTSDMMEACECPA1ACE2 | |
| SCHEMBL30052878 | 0.83 | FNTA (0.48) | BACE1FNTAFNTBCTSD | |
| SCHEMBL30050856 | 0.82 | ALDH1A1 (0.41) | FNTAFNTBMMEACECPA1 | |
| SCHEMBL30051213 | 0.82 | FNTA (0.44) | FNTAFNTBCTSDENPEP | |
| SCHEMBL30051389 | 0.82 | FNTA (0.46) | FNTAFNTBCTSDENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727937-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | Vivoryon Therapeutics N.V. (DE) | 2026-04-22 | — | — | EP | disclosed |
| US-20250154129-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2025-05-15 | — | — | US | disclosed |
| US-20250026738-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2025-01-23 | — | — | US | disclosed |
| WO-2024256618-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | VIVORYON THERAPEUTICS N.V. (DE) | 2024-12-19 | — | — | WO | disclosed |
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | VIVORIAN THERAPEUTICS N.V | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11279690-B2 | Inhibitors of glutaminyl cyclase | QPCT, QPCTL, GLUL | BACE1 1760/4885FNTA 76/4885FNTB 179/4885 |
| US-20250154129-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | QPCT, GLS, QPCTL | BACE1 3204/4885FNTA 291/4885FNTB 1664/4885 |
| US-20250026738-A1 | CRYSTALLINE PHARMACEUTICALLY ACCEPTABLE SALT AND POLYMORPHIC FORM OF THE GLUTAMINYL CYCLASE INHIBITOR VAROGLUTAMSTAT | QPCT, GLS, QPCTL | BACE1 3204/4885FNTA 291/4885FNTB 1664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.